WEBULL
News
AWHL
0.418
+2.05%
0.008
Weekly Report: what happened at AWHL last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at AWHL last week (1117-1121)?
Weekly Report · 11/24 10:11
Weekly Report: what happened at AWHL last week (1110-1114)?
Weekly Report · 11/17 10:11
Aspira Women’s Health Reports Q3 2025 Financials
TipRanks · 11/15 04:00
Aspira Women's Health Inc. reports Q3 product revenue of $2.3 million and net loss of $4.9 million
Reuters · 11/14 12:44
Aspira Women’s Health GAAP EPS of -$0.13, revenue of $2.31M
Seeking Alpha · 11/14 12:40
Aspira Women's Health Reports Flat Q3 Revenue and Higher Gross Margin
Reuters · 11/14 12:35
Aspira: Q3 Earnings Snapshot
Barchart · 11/14 06:41
Weekly Report: what happened at AWHL last week (1103-1107)?
Weekly Report · 11/10 10:08
Aspira Women's Health Corrects Warrant Termination Date in SEC Filing
Reuters · 11/03 21:17
Weekly Report: what happened at AWHL last week (1027-1031)?
Weekly Report · 11/03 10:09
Aspira Women's Health Secures Laboratory Services Agreement with University of Texas Medical Branch
Reuters · 10/29 11:02
Aspira Women’s Health Advances Endometriosis Diagnosis with EndoCheck Study
TipRanks · 10/27 18:42
Weekly Report: what happened at AWHL last week (1020-1024)?
Weekly Report · 10/27 10:11
Weekly Report: what happened at AWHL last week (1013-1017)?
Weekly Report · 10/20 10:08
Aspira Women’s Health Upgrades to OTCQX Market
Barchart · 10/16 16:02
Weekly Report: what happened at AWHL last week (1006-1010)?
Weekly Report · 10/13 10:11
Weekly Report: what happened at AWHL last week (0929-1003)?
Weekly Report · 10/06 10:08
Weekly Report: what happened at AWHL last week (0922-0926)?
Weekly Report · 09/29 10:08
More
Webull provides a variety of real-time AWHL stock news. You can receive the latest news about Aspira Womens Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About AWHL
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.